MDGL Stock Overview
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.
Madrigal Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$66.19|
|52 Week High||US$131.92|
|52 Week Low||US$52.33|
|1 Month Change||-12.44%|
|3 Month Change||-24.00%|
|1 Year Change||-47.34%|
|3 Year Change||-32.71%|
|5 Year Change||333.18%|
|Change since IPO||552.11%|
Recent News & Updates
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate
Today we will run through one way of estimating the intrinsic value of Madrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL...
Madrigal: NASH Data In Q4 Is The Key
MDGL announced NAFLD data in January. The 2018 NASH data has some predictive value for the phase 3 NASH trial. This trial will produce data in Q4.
We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
|MDGL||US Biotechs||US Market|
Return vs Industry: MDGL underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: MDGL underperformed the US Market which returned -12.9% over the past year.
|MDGL Average Weekly Movement||8.8%|
|Biotechs Industry Average Movement||12.3%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: MDGL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: MDGL's weekly volatility (9%) has been stable over the past year.
About the Company
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom.
Madrigal Pharmaceuticals Fundamentals Summary
|MDGL fundamental statistics|
Is MDGL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MDGL income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-14.43|
|Net Profit Margin||0.00%|
How did MDGL perform over the long term?See historical performance and comparison
Is Madrigal Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MDGL ($66.19) is trading below our estimate of fair value ($1299.66)
Significantly Below Fair Value: MDGL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MDGL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: MDGL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MDGL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MDGL is overvalued based on its PB Ratio (7.8x) compared to the US Biotechs industry average (1.5x).
How is Madrigal Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDGL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MDGL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MDGL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MDGL's revenue (76.5% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: MDGL's revenue (76.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MDGL is forecast to be unprofitable in 3 years.
How has Madrigal Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MDGL is currently unprofitable.
Growing Profit Margin: MDGL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MDGL is unprofitable, and losses have increased over the past 5 years at a rate of 48% per year.
Accelerating Growth: Unable to compare MDGL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDGL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: MDGL has a negative Return on Equity (-169.35%), as it is currently unprofitable.
How is Madrigal Pharmaceuticals's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MDGL's short term assets ($221.2M) exceed its short term liabilities ($76.6M).
Long Term Liabilities: MDGL's short term assets ($221.2M) exceed its long term liabilities ($283.0K).
Debt to Equity History and Analysis
Debt Level: MDGL is debt free.
Reducing Debt: MDGL had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MDGL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MDGL has less than a year of cash runway if free cash flow continues to reduce at historical rates of 48.4% each year
What is Madrigal Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MDGL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MDGL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MDGL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MDGL's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MDGL has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul Friedman (78 yo)
Dr. Paul A. Friedman, M.D., has been Independent Chairman of the Board at Prelude Therapeutics Incorporated and has been its Independent Director since July 2016. He has been Chairman and Chief Executive O...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD5.32M) is above average for companies of similar size in the US market ($USD3.94M).
Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.
Experienced Management: MDGL's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Experienced Board: MDGL's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.1%.
Madrigal Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Madrigal Pharmaceuticals, Inc.
- Ticker: MDGL
- Exchange: NasdaqGS
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.132b
- Shares outstanding: 17.10m
- Website: https://www.madrigalpharma.com
Number of Employees
- Madrigal Pharmaceuticals, Inc.
- Four Tower Bridge
- Suite 200
- West Conshohocken
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.